Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 10/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 3/20 | 0.39 |
| ▸ | FFAR4 | Q5NUL3 | 3/20 | 0.37 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 1/20 | 0.36 |
| ▸ | HTR2B | P41595 | 1/20 | 0.36 |
| ▸ | FABP4 | P15090 | 2/20 | 0.35 |
| ▸ | FABP5 | Q01469 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10148306 | 0.90 | SCN9A (0.41) | SCN9ARXFP1FFAR4HTR2AHTR2C | |
| SCHEMBL10185065 | 0.84 | SCN9A (0.41) | SCN9ARXFP1HTR2AHTR2CHTR2B | |
| SCHEMBL10148298 | 0.82 | LMNA (0.51) | FFAR4 | |
| SCHEMBL10148299 | 0.82 | HRH3 (0.45) | SCN9AFFAR4 | |
| SCHEMBL10148321 | 0.81 | FFAR4 (0.37) | FFAR4FABP4FABP5 | |
| SCHEMBL24515566 | 0.80 | RXFP1 (0.41) | RXFP1FFAR4 | |
| SCHEMBL10148300 | 0.77 | PDE4D (0.41) | FFAR4 | |
| SCHEMBL661513 | 0.77 | ALDH1A1 (0.43) | SCN9ARXFP1 | |
| SCHEMBL661512 | 0.77 | ALDH1A1 (0.43) | SCN9ARXFP1 | |
| SCHEMBL10148349 | 0.77 | ALDH1A1 (0.43) | SCN9ARXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120046292-A1 | DIACYLETHYLENEDIAMINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2012-02-23 | — | — | US | disclosed |
| US-20120046292-A1 | DIACYLETHYLENEDIAMINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2012-02-23 | — | — | US | disclosed |
| WO-2010122968-A1 | DIACYLETHYLENEDIAMINE COMPOUND | アステラス製薬株式会社 (JP) | 2010-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120046292-A1 | DIACYLETHYLENEDIAMINE COMPOUND | DGAT1, DGAT2, DIMT1 | SCN9A 3832/4885RXFP1 3304/4885FFAR4 1053/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.